抗凝药物在经颈静脉肝内门体分流术后的应用

蒋明远; 黄华; 路明亮; 林凡榆; 张映媛

doi:10.3969/j.issn.1001-5256.2018.10.040

抗凝药物在经颈静脉肝内门体分流术后的应用

DOI: 10.3969/j.issn.1001-5256.2018.10.040

昆明医科大学第二附属医院消化内科

基金项目:

云南省应用基础研究(2015FB059)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2092
- HTML全文浏览量: 47
- PDF下载量: 383
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-28
- 出版日期: 2018-10-20

Application of anticoagulants after transjugular intrahepatic portosystemic shunt

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University

Research funding:

摘要

摘要: 经颈静脉肝内门体分流术(TIPS)经过近30年的不断探索与发展,目前已被广泛应用于治疗门静脉高压并发症,TIPS在急性食管胃底静脉曲张破裂出血、预防再出血、顽固性腹腔积液、布加综合征等方面有明显的优势,但如果术后抗凝措施不当,会引起支架功能障碍、急性血栓形成等并发症,导致TIPS术前门静脉高压症状再现,严重影响了术后中、远期疗效及患者存活率,而维持支架畅通是保证术后疗效的关键,因此抗凝药物在预防和治疗TIPS术后血栓形成显得极为重要,目前关于TIPS术后抗凝治疗国内外还没有达成共识,就TIPS术后抗凝药物应用的研究进展作一综述。
- 门体分流术,经颈静脉肝内 /
- 静脉血栓形成 /
- 抗凝药 /
- 综述
Abstract: Transjugular intrahepatic portosystemic shunt ( TIPS) , after nearly 30 years of continuous exploration and development, has been widely used in the treatment of complications of portal hypertension. TIPS has significant advantages in acute esophagogastric variceal bleeding, prevention of rebleeding, refractory peritoneal effusion, and Budd-Chiari syndrome; however, if postoperative anticoagulant measures are inappropriate, it can cause several complications, such as stent dysfunction and acute thrombosis, and lead to the recurrence of the symptoms of portal hypertension before TIPS, which greatly affects middle-and long-term clinical outcomes and survival rate. Maintenance of stent patency is the key to good postoperative treatment outcome, and therefore, anticoagulants play an important role in the prevention and treatment of post-TIPS thrombosis. At present, no consensus has been reached on post-TIPS anticoagulant therapy in China and foreign countries. This article reviews the research advances in the application of anticoagulants after TIPS.
- portasystemic shunt, transjugular intrahepatic /
- venous thrombosis /
- anticoagulants /
- review

HTML全文

参考文献(41)

[1]ZHANG Y, ZHANG H, ELIZABETH A, et al.Epidemiology o hepatitis B and associated liver diseases in China[J].Chin Med Sci J, 2012, 27 (4) :243-248.

[2]BOSCH J, ABRALDES J, GROSZMANN R.Current management o portal hypertension[J].J Hepatol, 2003, 38 (1) :54-68.

[3]QI XS, BAI M, YANG ZP, et al.Selection of a TIPS stent for management of portal hypertension in liver cirrhosis:An evidencebased review[J].World J Gastroenterol, 2014, 20 (21) :6470-6480.

[4]ORLOFF MJ, HYE RJ, WHEELER HO, et al.Randomized trials of endoscopic therapy and transjugular intrahepatic portosystemic shunt versus portacaval shunt for emergency and elective treatment of bleeding gastric varices in cirrhosis[J].Surgery, 2015, 157 (6) :1028-1045.

[5]GARCA-PAGN JC, CACA K, BUREAU C, et al.Early use of TIPS in patients with cirrhosis and variceal bleeding[J].Ann Intern Med, 2010, 153 (10) :5-13.

[6]SUHOCKI PV, LUNGREN MP, KAPOOR B, et al.Transjugular intrahepatic portosystemic shunt complications:prevention and management[J].Semin Intervent Radiol, 2015, 32 (2) :123.

[7]WAN YM, LI YH, WU HM, et al.Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement:An observational study (STROBE compliant) [J].Medicine, 2017, 96 (45) :e8498.

[8]GAZZERA C, RIGHI D, DORIGUZZI BA, et al.Emergency transjugular intrahepatic portosystemic shunt (TIPS) :results, complications and predictors of mortality in the first month of follow-up[J].Radiol Med, 2012, 117 (1) :46-53.

[9]BAI M, HE CY, QI XS, et al.Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt[J].World J Gastroenterol, 2014, 20 (3) :774-785.

[10]BUREAU C, GARCIA-PAGAN JC, OTAL P, et al.Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS:Results of a randomized study[J].Gastroenterology, 2004, 126 (2) :469-475.

[11]PAN JJ, CHEN C, GELLER B, et al.Is sonographic surveillance of polytetrafluoroethylene-covered transjugular intrahepatic portosystemic shunts (TIPS) necessary?A single centre experience comparing both types of stents[J].Clin Radiol, 2008, 63 (10) :1142-1148.

[12]MENZEL J, VESTRING T, FOERSTER EC, et al.Arterio-biliary fistula after transjugular intrahepatic portosystemic shunt:A lifethreatening complication of the new technique for therapy of portal hypertension[J].Z Gastroenterol, 1995, 33 (5) :255-259.

[13]CURA M, CURA A, SURI R, et al.Causes of TIPS dysfunction[J].Ajr Am J Roentgenol, 2008, 191 (6) :1751-1757.

[14]BAGLIN T, BARROWCLIFFE TW, COHEN A, et al.Guidelines on the use and monitoring of heparin[J].Br J Haematol, 2006, 133 (1) :19-34.

[15]UCHIDA Y, MORI F, OGAWA H, et al.Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents[J].J Cardiol, 2010, 55 (3) :362-369.

[16]RSSLE M, GERBES AL.TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax:A critical update[J].Gut, 2010, 59 (7) :988-990.

[17]COLOMBATO L.The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension[J].Hepatology, 2010, 51 (1) :386-400.

[18]DE FR, FACULTY BV.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.

[19]OFLIVER EAF.EASL clinical practice guidelines:Vascular diseases of the liver[J].J Hepatol, 2016, 64 (1) :179-202.

[20]VEITCH AM, VANBIERVLIET G, GERSHILICH AH, et al.Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants:British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines[J].Endoscopy, 2016, 48 (04) :385-402.

[21]Interventional Group, Chinese Society of Radiology, Chinese Medical Association.Expert consensus on transjugular intrahepatic portosystemic shunt[J].J Clin Hepatol, 2017, 33 (7) :1218-1228. (in Chinese) 中华医学会放射学分会介入学组.经颈静脉肝内门体分流术专家共识[J].临床肝胆病杂志, 2017, 33 (7) :1218-1228.

[22]SENZOLO M, RODRIGUEZ-CASTRO KI, ROSSETTO V, et al.Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis[J].J Thromb Haemost, 2012, 10 (9) :1823-1829.

[23]BECHMANN LP, SICHAU M, WICHERT M, et al.Low-molecular-weight heparin in patients with advanced cirrhosis[J].Liver Int, 2015, 31 (1) :75-82.

[24]RSSLE M, BAUSCH B, KLINGER C.Therapy algorithm for portal vein thrombosis in liver cirrhosis:The internist's point of view[J].Viszeralmedizin, 2014, 30 (6) :401-408.

[25]WAN YM, LI YH, WU HM, et al.Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt[J].Clin Appl Thromb Hemost, 2018, 24 (3) :462-470.

[26]LI LX, YI SP, LIANG FF, et al.Analysis of the influence factors of portal vein thrombosis after TIPS[J].Mod Digest Interv, 2017, 22 (6) :772-776. (in Chinese) 黎丽旋, 易颂平, 梁芬芬, 等.TIPS术后门静脉血栓形成的影响因素分析[J].现代消化及介入诊疗, 2017, 22 (6) :772-776.

[27]WANG Z, JIANG MS, ZHAGN HL, et al.Is Post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis?A randomized controlled trial[J].Radiology, 2016, 279 (3) :943-951.

[28]INTAGLIATA NM, HENRY ZH, SHAH N, et al.Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding[J].Liver Int, 2014, 34 (1) :26-32.

[29]JAMES K, BERTOJA E, O'BEIRNE J, et al.Use of thromboelastography Platelet Mapping to monitor antithrombotic therapy in a patient with Budd-Chiari syndrome[J].Liver Transpl, 2010, 16 (1) :38-41.

[30]DING Y, WANG LZ, SONG J, et al.The influence of CYP2C19 gene polymorphism on the curative effect of clopidogrel in patients after receiving TIPS[J].J Intervent Radiol, 2017, 26 (7) :588-593. (in Chinese) 丁远, 王黎洲, 宋杰, 等.细胞色素P450酶2C19基因多态性对TIPS术后患者服用氯吡格雷效果的影响[J].介入放射学杂志, 2017, 26 (7) :588-593.

[31]TUMMALA R, KAVTARADZE A, GUPTA A, et al.Specific antidotes against direct oral anticoagulants:A comprehensive review of clinical trials data[J].Int J Cardiol, 2016, 214:292-298.

[32]LAUX V, PERZBORN E, KUBITA D, et al.Preclinical and clinical characteristics of rivaroxaban:a novel, oral, direct factor Xa inhibitor[J].Semin Thromb Hemost, 2007, 33 (5) :515-523.

[33]YANG R, XU HS, ZHANG ZL, et al.Effect of drug interaction on anticoagulant strength of warfarin[J].Chin J Clin Pharmacol Ther, 2017, 22 (12) :1426-1431. (in Chinese) 杨瑞, 许海沙, 张赞玲, 等.药物相互作用对华法林抗凝强度的影响分析[J].中国临床药理学与治疗学, 2017, 22 (12) :1426-1431.

[34]VILASECA M, GARCA-CALDERH, LAFOZ E, et al.The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells[J].Hepatology, 2017, 65 (6) :2031.

[35]LISMAN T, KAMPHUISEN PW, NORTHUP PG, et al.Established and new-generation antithrombotic drugs in patients with cirrhosis-Possibilities and caveats[J].J Hepatol, 2013, 59 (2) :358-366.

[36]LI XY, LU Y, LIU YX, et al.Compare anticoagulation effects of rivaroxaban with low molecular weight heparin in patients after transjugular intrahepatic portasystemic stent shunt[J].Chin J New Drugs Clin Remed, 2016, 35 (6) :419-422. (in Chinese) 黎小妍, 陆英, 刘玉兴, 等.利伐沙班与低分子肝素对经颈静脉肝内门体分流术后患者的抗凝疗效比较[J].中国新药与临床杂志, 2016, 35 (6) :419-422.

[37]GRAFF J, HARDER S.Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment[J].Clin Pharmacokinet, 2013, 52 (4) :243-254.

[38]STANGIER J, STAHLE H, RATHGEN K, et al.Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment[J].J Clin Pharmacol, 2008, 48 (12) :1411-1419.

[39]STANGIER DJ, RATHGEN K, STAHLE H, et al.Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate[J].Clin Pharmacokinet, 2010, 49 (4) :259-268.

[40]BLOMMEL ML, BLOMMEL AL.Dabigatran etexilate:A novel oral direct thrombin inhibitor[J].Am J Health Syst Pharm, 2011, 68 (16) :1506-1519.

[41]TAKEUCHI H.A network of pulmonary vein thrombi is a risk factor for ischemic stroke, especially after cardiac surgery:A case report and mini review[J].Int J Cardiol Heart Vasc, 2015, 6:1-3.

施引文献

资源附件(0)

访问统计